Pharmaceutical PTC Therapeutics announced today that, at the end of last week, the US Food and Drug Administration’s Office of Drug Evaluation I (ODE-I) denied the company's first appeal of the refuse to file letter issued by the FDA's Division of Neurological Products (DNP) on February 22, 2016 regarding PTC's New Drug Application for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). 17 October 2016